CD46 and breast carcinoma: Our screen assessed several known CD markers and identified several novel (i.e. CD63, CD98 and CD164) and less characterised (i.e. CD46, CD107a and CD321) breast epithelial markers, of which are overexpressed in at least 5% of breast cancer samples in the COSMIC database [38].